Bicara Therapeutics Inc. BCAX

BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that, effective August 12, 2026, it awarded an inducement grant to Jennifer Larson under Bicara’s 2026 Inducement Plan as a material inducement to her commencement of employment as Bicara’s Chief Financial Officer. Ms. Larson received a non-qualified stock option to

Bicara Therapeutics recently reported second-quarter 2026 results showing a wider net loss of US$55.44 million and higher loss per share, alongside filing a US$19.41 million employee stock offering shelf registration. At the same time, the company outlined a broad leadership reshuffle and ongoing preparation for possible commercialization of ficerafusp alfa, as its pivotal FORTIFI-HN01 trial in HPV-negative head and neck cancer advances toward an interim readout expected in mid-2027. We’ll...